PharmaNutra stock

PHN · Borsa Italiana · EUR

Compare PharmaNutra
€85.80Change from previous close: −1.72%Absolute change: −€1.50

Close · November 20, 2026

Price history

+71.60% over the period

1 year: from €50.00 (November 20, 2025) to €85.80 (November 20, 2026), +71.60%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026€85.80
October 30, 2026€71.00
September 30, 2026€73.10
August 31, 2026€82.00
July 31, 2026€83.20
June 30, 2026€87.70
May 29, 2026€90.60
April 30, 2026€78.80
March 31, 2026€78.70
February 27, 2026€67.00
January 30, 2026€63.10
December 30, 2025€54.30
November 28, 2025€58.00
November 20, 2025€50.00

At a glance

  • The company

    Research, develop and market food supplements, medical devices and raw materials for nutraceutical and pharmaceutical industries

  • Latest results

    Quarter to September 30, 2026 · EPS €0.74 (estimate €0.83)

TickerLandia's take on PharmaNutra

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€48.95
52-wk high€95.90

−10.53% from the 52-week high

Analysts · 3 analysts

Average target€96.00+11.89% vs. price

Buy 3 · Hold 0 · Sell 0 · Strong buy

TickerLandia Fingerprint: PharmaNutra

Compared with similar companies: strong momentum, high growth, and high price.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

PharmaNutra is pricier than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), PharmaNutra's P/E today is 41.1, above the median of its last 9 fiscal years (26.8; between 17.1 and 53.0 from 2017 to 2025). PharmaNutra's P/E (trailing 12 months): 36.7, +88% against the median of a group of 9 similar companies (19.5).

P/E compared with its history

Compared with 9 similar companies

PharmaNutra's metrics compared with similar companies
MetricPharmaNutraPosition in the groupBand
P/E (trailing 12 months)36.7High
Forward P/E26.4High
Operating margin22.0%Middle
ROE32.4%High
Debt/equity0.26Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: PharmaNutra. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€40.5M

Latest quarter · Q2 2026

Net income

€6.47M

Latest quarter · Q2 2026

Quarterly net margin

16.0%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
€834.95M
P/E
36.7
EPS
€2.38
Volume
9.76K
Daily trading
€1.22M
Dividend yield
1.40%
Last ex-dividend on May 4, 2026

How PharmaNutra is changing

All results
  • Revenue grew 18.4% a year on average over the last 5 years

  • Operating margin fell from 27.8% to 22.0%

  • Free cash flow equal to 64% of net income

Returns

PharmaNutra returns with dividends

€1,000 invested in PharmaNutra 5 years ago, on November 22, 2021, would be worth €1,265 today with dividends reinvested: +26.48% in total, +4.82% per year. On price alone it would be €1,172 (+17.21%).

PeriodPharmaNutraFTSE MIB€1,000 becomes
1 month+21.02%−0.75%€1,210
6 months−2.50%−0.97%€975
Year to date+58.01%+8.36%€1,580
1 year+74.18%+13.48%€1,742
3 years+71.10%+64.86%€1,711
5 years+26.48%+77.86%€1,265

Over the last 6 months it has done better than 20% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. FTSE MIB: price only. Calculate your investment

The chart in detail

PharmaNutra: technical analysis

PharmaNutra shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 7.6% below its all-time closing high (€92.90, June 8, 2026).

Trend
No clear trend
RSI (14 sessions)
72
Above 70: a strong rise in a short time
vs 200-session average
+8.34%

Active signals

  • RSI above 70: the stock has risen a lot in a short time.

    since November 10, 2026

Support and resistance

Price areas where PharmaNutra has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance€91.10+6.18%2 touches, last on July 8, 2026
  2. Last price€85.80
  3. Support€85.60−0.23%3 touches, last on August 11, 2026
  4. Support€83.47−2.72%3 touches, last on September 8, 2026
  5. Support€81.00−5.59%2 touches, last on July 30, 2026

Volatility and risk

Over the last year it has moved little with the FTSE MIB.

Beta (1 year) vs FTSE MIB
0.11
Volatility (60 sessions, annualised)
38.2%
Largest fall in the last year
−24.43%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

PharmaNutra: seasonality

Average monthly price change over 10 years

+1.1%Jan+0.3%Feb+0.3%Mar+0.9%Apr+3.1%May+3.4%Jun+0.7%Jul+3.6%Aug−2.1%Sep+1.8%Oct+5.2%Nov+4.4%Dec

Over the last 10 years, the strongest month for PharmaNutra has been November: +5.23% on average, positive in 7 years out of 9. The weakest has been September: −2.10% on average, positive in 4 years out of 10.

Show chart data
MonthAverageMedianPositive years
January+1.13%−0.43%4 of 9
February+0.30%+0.30%5 of 9
March+0.33%+0.29%5 of 9
April+0.89%+1.76%6 of 9
May+3.05%+1.24%5 of 9
June+3.36%−3.20%4 of 9
July+0.71%−0.43%3 of 9
August+3.64%+0.61%6 of 10
September−2.10%−2.14%4 of 10
October+1.79%+0.70%6 of 10
November+5.23%+4.41%7 of 9
December+4.39%+1.20%5 of 9

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

PharmaNutra and its competitors

Customers in Europe, the Middle East, the Far East, North America, South America and other regions buy the food supplements and medical devices that Pharmanutra develops, makes and markets. Its nutraceutical operations also supply raw materials and active ingredients to food, pharmaceutical and dietary supplement manufacturers. Among its branded products, Sucrosomial is a delivery system designed to improve nutrient absorption while limiting gastrointestinal side effects, and Cetylated Fatty Acids supports muscles and joints after physical therapy and training.

Headquarters
Pisa, Italy
Employees
146
Founded
2000
Chief executive
Roberto Lacorte
PharmaNutra and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
PharmaNutraPHN$917.61M22.0%36.7−2.50%
EvotecEVT$489.39M-18.0%—−48.86%
Faes FarmaFAE$1.65B13.0%17.9+4.66%
FagronFAGR$1.97B14.3%19.5−0.20%
AlmirallALM$2.45B9.6%30.2−9.84%
Siegfried HoldingSFZN$3.4B16.7%16.7−19.46%

Same industry or related industries, similar size. Compare PharmaNutra with its competitors · Full profile